Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06204315 · ClinicalTrials.gov registry record · Phase 2
Risk Adapted Spinal Cord/Cauda Constraint Relaxation for High-risk Patients With Metastatic Epidural Spinal Cord Compression Undergoing Spine Stereotactic Radiosurgery
A Phase 2 study of Spinal Cord and Metastatic Epidural, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06204315 is a Phase 2 study of Spinal Cord and Metastatic Epidural that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06204315, a Phase 2 study of Spinal Cord and Metastatic Epidural, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn about the safety of a procedure called cord dose escalated spine stereotactic radiosurgery (CDE-SSRS) in patients with MESCC.
Conditions Studied
Interventions
- RADIATION Stereotactic Radiosurgery
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-11-11 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06204315
The ClinicalTrials.gov registry entry for NCT06204315 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Spinal Cord appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic Radiosurgery is the first listed.
NCT06204315 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06204315 about?
NCT06204315 is a clinical study titled "Risk Adapted Spinal Cord/Cauda Constraint Relaxation for High-risk Patients With Metastatic Epidural Spinal Cord Compression Undergoing Spine Stereotactic Radiosurgery". To learn about the safety of a procedure called cord dose escalated spine stereotactic radiosurgery (CDE-SSRS) in patients with MESCC.
What is the current status of trial NCT06204315?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-11-11. Estimated completion is 2029-12-31.
What conditions does trial NCT06204315 study?
This clinical trial studies the following conditions: Spinal Cord, Metastatic Epidural, Spine Stereotactic.
What interventions are being tested in trial NCT06204315?
The interventions under investigation include: Stereotactic Radiosurgery (RADIATION).
Who is sponsoring clinical trial NCT06204315?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06204315 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.